Andrew Kuykendall, MD, discusses the investigation of navitoclax plus ruxolitinib in myelofibrosis.
Andrew Kuykendall, MD
Advertisement
Andrew Kuykendall, MD, is an assistant member in the Department of Malignant Hematology at the Moffitt Cancer Center in Tampa, Florida.
Articles by Andrew Kuykendall, MD
Andrew Kuykendall, MD, discusses the evaluation of momelotinib in patients with symptomatic and anemic myelofibrosis.
Andrew Kuykendall, MD, discusses treatment considerations with ruxolitinib in myelofibrosis.
Andrew Kuykendall, MD, discusses the evolution of prognostication factors in primary and secondary myelofibrosis.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer
2
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
3
Perioperative Pembrolizumab/Enfortumab Vedotin Approved in Europe for Cisplatin-Ineligible MIBC
4
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
5